# Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC), Division 3.3.5

Extent: E+W+S+N.I.

NAT assays may be used to detect virus in antibody negative samples, i.e. pre-sero-conversion samples. Viruses within immune-complexes may behave differently in comparison to free viruses, for example during a centrifugation step. It is therefore important that during robustness studies, antibody-negative (pre-sero-conversion) samples are included.

---
Source: https://www.legislation.gov.uk/eudn/2002/364/annex/division/3/division/3.3/division/3.3.5 (the official version)
Page: https://openlegislation.uk/eu-decision-2002-364/annex/division-3/division-3.3/division-3.3.5
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.